- |||||||||| zibotentan (ZD4054) / AstraZeneca
Trial completion, Enrollment change, Trial primary completion date: ZEBRA: Zibotentan Better Renal Scleroderma Outcome Study (clinicaltrials.gov) - Oct 31, 2017 P2, N=27, Completed, Recruiting --> Completed | N=72 --> 27 | Trial primary completion date: Oct 2016 --> Oct 2017
- |||||||||| Trial completion: Psychological Treatments for Scleroderma (clinicaltrials.gov) - Aug 8, 2017
P2, N=89, Completed, Recruiting --> Completed | N=72 --> 27 | Trial primary completion date: Oct 2016 --> Oct 2017 No longer recruiting --> Completed
- |||||||||| cyclophosphamide / Generic mfg.
Trial completion: Scleroderma Lung Disease (clinicaltrials.gov) - Feb 27, 2016 P3, N=158, Completed, N=500 --> 0 | Not yet recruiting --> Withdrawn No longer recruiting --> Completed
- |||||||||| Trial completion: The CARRA Registry (clinicaltrials.gov) - Nov 17, 2015
P=N/A, N=9587, Completed, Recruiting --> Completed | N=12 --> 7 | Trial primary completion date: Dec 2016 --> Jun 2014 Enrolling by invitation --> Completed
- |||||||||| Tracleer (bosentan) / J&J, Roche
Trial primary completion date: ScS-REINBO: Effect of Bosentan in Scleroderma Renal Crisis (clinicaltrials.gov) - Oct 22, 2015 P2, N=16, Active, not recruiting, Enrolling by invitation --> Completed Trial primary completion date: Jul 2015 --> Oct 2015
- |||||||||| Enrollment status: The CARRA Registry (clinicaltrials.gov) - Apr 23, 2015
P=N/A, N=10000, Enrolling by invitation, N=20 --> 0 Recruiting --> Enrolling by invitation
- |||||||||| cyclophosphamide / Generic mfg.
Enrollment closed, Trial primary completion date: SCOT Scleroderma Treatment Alternative Registry (STAR Registry) (clinicaltrials.gov) - Apr 14, 2015 P=N/A, N=45, Active, not recruiting, Recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Mar 2016
- |||||||||| Dysport (abobotulinumtoxinA) / Ipsen, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment open, Trial initiation date: Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome (clinicaltrials.gov) - Jan 13, 2015 P3, N=40, Recruiting, N=50 --> 23 Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Jan 2015
- |||||||||| zibotentan (ZD4054) / AstraZeneca
Enrollment open, Trial primary completion date: ZEBRA: Zibotentan Better Renal Scleroderma Outcome Study (clinicaltrials.gov) - Nov 20, 2014 P2, N=72, Recruiting, Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Oct 2016
- |||||||||| Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Trial completion, Enrollment change: A Study of the Safety and Tolerability of MEDI-551 in Scleroderma (clinicaltrials.gov) - Nov 13, 2014 P1, N=50, Completed, Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Oct 2016 Active, not recruiting --> Completed | N=27 --> 50
- |||||||||| Trial primary completion date: Finger Hardness Measure in Scleroderma (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=60, Completed, Active, not recruiting --> Completed | N=27 --> 50 Trial primary completion date: Sep 2013 --> Jan 2013
- |||||||||| Trial completion, Trial primary completion date: Finger Hardness Measure in Scleroderma (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=60, Completed, Trial primary completion date: Sep 2013 --> Jan 2013 Enrolling by invitation --> Completed | Trial primary completion date: Sep 2013 --> Jan 2013
|